🇺🇸 FDA
Pipeline program

Trastuzumab deruxtecan

D9670C00001

Phase 3 small_molecule active

Quick answer

Trastuzumab deruxtecan for Advanced or Metastatic Breast Cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Advanced or Metastatic Breast Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials